Edralbrutinib
As of the edition of 20 October 2026, Edralbrutinib is a small molecule: stopped in 2024; acts on BTK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Eye; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Edralbrutinib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BTK | Tyrosine-protein kinase BTK | Q06187 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 4 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2018 to now |
| TG Therapeutics | Lead sponsor of trials | 2018 to now |
| Reistone Biopharma | Lead sponsor of trials | 2021 to now |